A disruptive technology to tackle brain cancer and glioblastoma
News
Positive FDA feedback on Hemerion’s clinical strategy for glioblastoma
The Food and Drug Administration (FDA) has issued a positive feedback on Hemerion’s clinical strategy following a Type C Meeting held in November 2025. The U.S. health authority confirmed the… ...
Hemerion’s breakthrough glioblastoma approach featured in new peer-reviewed case report
A newly published case report in the renowned Journal of Neuro-Oncology Discovery provides compelling clinical evidence of the feasibility, safety and workflow integration of the Pentalafen®/Heliance® combination therapy in treating… ...
International development: Hemerion wins the national LeadExport Trophy
Le Moci, the leading media outlet serving international trade professionals in France, awarded Hemerion the nationale LeadExport Trophy in the Innovation category in recognition of its international activities. This award… ...
Stay tuned to our clinical advances
They talk about us
